DK1506190T3 - (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker - Google Patents

(Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker

Info

Publication number
DK1506190T3
DK1506190T3 DK03752750T DK03752750T DK1506190T3 DK 1506190 T3 DK1506190 T3 DK 1506190T3 DK 03752750 T DK03752750 T DK 03752750T DK 03752750 T DK03752750 T DK 03752750T DK 1506190 T3 DK1506190 T3 DK 1506190T3
Authority
DK
Denmark
Prior art keywords
pyridazine
imidazol
methyl
nmda receptor
receptor blocker
Prior art date
Application number
DK03752750T
Other languages
Danish (da)
English (en)
Inventor
Neidhart Marie-Paule Heitz
Bernd Buettelmann
Georg Jaeschke
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1506190T3 publication Critical patent/DK1506190T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03752750T 2002-05-16 2003-05-16 (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker DK1506190T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16

Publications (1)

Publication Number Publication Date
DK1506190T3 true DK1506190T3 (da) 2006-10-16

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03752750T DK1506190T3 (da) 2002-05-16 2003-05-16 (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker

Country Status (31)

Country Link
US (1) US7005432B2 (xx)
EP (1) EP1506190B1 (xx)
JP (1) JP4267569B2 (xx)
KR (1) KR100632868B1 (xx)
CN (1) CN1312151C (xx)
AR (1) AR040010A1 (xx)
AT (1) ATE329912T1 (xx)
AU (1) AU2003242542B2 (xx)
BR (1) BR0311177A (xx)
CA (1) CA2485926C (xx)
CL (1) CL2004001251A1 (xx)
CY (1) CY1105159T1 (xx)
DE (1) DE60306152T2 (xx)
DK (1) DK1506190T3 (xx)
ES (1) ES2265581T3 (xx)
HK (1) HK1080845A1 (xx)
HR (1) HRP20041060B1 (xx)
IL (1) IL164922A (xx)
MA (1) MA27117A1 (xx)
ME (1) MEP76708A (xx)
MX (1) MXPA04011253A (xx)
NO (1) NO329605B1 (xx)
NZ (1) NZ536310A (xx)
PL (1) PL211340B1 (xx)
PT (1) PT1506190E (xx)
RS (1) RS51200B (xx)
RU (1) RU2317294C2 (xx)
SI (1) SI1506190T1 (xx)
TN (1) TNSN04224A1 (xx)
WO (1) WO2003097637A1 (xx)
ZA (1) ZA200408789B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
WO2006117052A1 (de) 2005-05-03 2006-11-09 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung und in deren herstellung verwendete boronsäure- und borinsäure-derivate
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2393360B1 (en) 2009-02-05 2015-11-04 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US8883788B2 (en) 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
ES2791186T3 (es) * 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Triazoles como inhibidores de receptores NR2B
BR112018016329A2 (pt) 2016-02-10 2018-12-18 Janssen Pharmaceutica Nv 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
CO2018008470A2 (es) 2016-02-18 2018-09-20 Syngenta Participations Ag Derivados de pirazol pesticídicamente activos
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
JP7346441B2 (ja) 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用
DK3830092T3 (en) 2018-08-03 2023-08-07 Novartis Ag Heteroaromatic nmda receptor modulators and uses thereof
CN113993583A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
JP2022538774A (ja) 2019-06-14 2022-09-06 ヤンセン ファーマシューティカ エヌ.ベー. ピリジンカルバメート及びglun2b受容体調節因子としてのそれらの使用
KR20220020915A (ko) 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도
MX2021015503A (es) 2019-06-14 2022-04-20 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
CA3142996A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032581A1 (en) * 1996-03-08 1997-09-12 F. Hoffmann-La Roche Ag Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers
CA2220649C (en) * 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
JP4219590B2 (ja) * 2000-04-20 2009-02-04 エフ.ホフマン−ラ ロシュ アーゲー ピロリジン及びピペリジン誘導体並びに神経変性障害の治療のためのこれらの使用
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
WO2002028814A2 (en) 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
PT1506190E (pt) 2006-11-30
PL211340B1 (pl) 2012-05-31
DE60306152T2 (de) 2007-04-26
CA2485926C (en) 2009-11-24
AU2003242542A1 (en) 2003-12-02
JP4267569B2 (ja) 2009-05-27
JP2005532326A (ja) 2005-10-27
HRP20041060B1 (en) 2012-11-30
BR0311177A (pt) 2005-03-15
WO2003097637A1 (en) 2003-11-27
EP1506190A1 (en) 2005-02-16
NZ536310A (en) 2007-08-31
DE60306152D1 (de) 2006-07-27
NO329605B1 (no) 2010-11-22
NO20044666L (no) 2004-12-15
AU2003242542B2 (en) 2008-10-16
IL164922A (en) 2012-01-31
PL374224A1 (en) 2005-10-03
US7005432B2 (en) 2006-02-28
TNSN04224A1 (fr) 2007-03-12
HK1080845A1 (en) 2006-05-04
RS98504A (xx) 2006-12-15
CL2004001251A1 (es) 2005-04-22
HRP20041060A2 (en) 2005-06-30
CY1105159T1 (el) 2009-11-04
MXPA04011253A (es) 2005-01-25
CN1653062A (zh) 2005-08-10
ATE329912T1 (de) 2006-07-15
MA27117A1 (fr) 2004-12-20
US20030229096A1 (en) 2003-12-11
KR100632868B1 (ko) 2006-10-13
CA2485926A1 (en) 2003-11-27
RS51200B (sr) 2010-12-31
EP1506190B1 (en) 2006-06-14
ZA200408789B (en) 2005-12-28
ES2265581T3 (es) 2007-02-16
AR040010A1 (es) 2005-03-09
SI1506190T1 (sl) 2006-10-31
RU2004136979A (ru) 2005-07-10
RU2317294C2 (ru) 2008-02-20
KR20040106558A (ko) 2004-12-17
CN1312151C (zh) 2007-04-25
IL164922A0 (en) 2005-12-18
MEP76708A (en) 2011-12-20

Similar Documents

Publication Publication Date Title
DK1506190T3 (da) (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
PL379420A1 (pl) Pochodne blokerów receptora angiotensyny II
DK1663996T3 (da) (Thio)carbamoylcyclohexanderivater som D3/D2-receptorantagonister
AU2003257094A1 (en) Substituted benzimidazole compounds
DE60328925D1 (de) Jittergenerator
EP1832069B8 (en) Voip network infrastructure components
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
ZA200409339B (en) Novel benzimidazole derivatives.
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
ZA200702209B (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
DK1802307T3 (da) Pyrrolidinderivater som histamin-receptor-ligander
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
AU2003902860A0 (en) Benzimidazole compounds
AU2003257032A1 (en) Antibodies against c3a receptor
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
DK1636221T3 (da) 3-Heterocyclyl-azetidin-forbindelser, som er nytte som NK1/NK2 receptorantagonister
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
DK1560828T3 (da) Imidazoquinolinderivater som adenosin-A3-receptorligander